NCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
Clinical Trials
21 trialsNCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT04072042 2025-05-14
BIOVAS
Ruijin Hospital
Phase 2 Recruiting
NCT06694324 2024-11-19
First-line Treatment of Advanced/unresectable DDLPS
Fudan University
Phase 2 Not yet recruiting
NCT04824352 2024-05-14
AIEO
Peking University People's Hospital
Phase 2 Suspended
NCT05905887 2024-02-28
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
Phase 2 Recruiting
NCT06140732 2023-11-20
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
Xuanwu Hospital, Beijing
Phase 2 Unknown
NCT06125171 2023-11-09
Tucidinostat Plus Apatinib for Advanced Osteosarcoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Unknown
NCT03742193 2023-11-01
PROACH
Ruijin Hospital
Phase 2 Unknown
NCT05751733 2023-03-02
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST
Xiangya Hospital of Central South University
Phase NA Recruiting
NCT04012827 2022-09-07
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Phase 2 Unknown
NCT04690231 2022-03-15
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Peking University People's Hospital
Phase NA Completed
NCT05265793 2022-03-04
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Fudan University
Phase 2 Unknown
NCT03104335 2020-05-19
Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
Peking University People's Hospital
Phase 2 Withdrawn
NCT04351308 2020-05-19
MAPAC
Peking University People's Hospital
Phase 2 Unknown
NCT04126811 2019-10-15
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT04126993 2019-10-15
Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03539172 2018-05-30
RASS
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Unknown
NCT02711007 2018-04-23
Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy
Peking University People's Hospital
Phase 2/3 Completed
NCT03121846 2017-05-22
Mesylate Apatinib for Stage â…£ STS After Failure of Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT03064243 2017-02-27
A Phase II Study of Apatinib in STS Patients
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Phase 2 Unknown